Lysosomal Enzyme Recovery Process
Enzyme replacement therapy (ERT) manufacturing — Protein A capture, ion exchange polishing, and formulation for Gaucher, Fabry, and Pompe disease treatments
Process Overview
Lysosomal enzyme replacement therapies (ERTs) treat rare genetic diseases caused by enzyme deficiencies. Products like imiglucerase (Cerezyme) for Gaucher disease, alglucosidase alfa (Myozyme) for Pompe disease, and agalsidase alfa (Replagal) for Fabry disease are produced in mammalian cell culture (CHO, human fibroblasts) and purified through chromatography-based downstream processing. The process shares similarities with monoclonal antibody purification but has unique aspects due to enzyme stability and mannose-targeting requirements.
Process Steps
1
Clarification
Harvest Clarification
Remove CHO cells and debris from bioreactor harvest by centrifugation (5,000–10,000 ×g) followed by depth filtration (0.2–0.65 μm). Add cell culture media components flocculants if needed. For perfusion cultures, use continuous clarification to maintain steady-state operation.
Yield: >98%
Removes: Cells, debris
2
Capture
Protein A Affinity Chromatography
Load clarified harvest onto Protein A Sepharose column at pH 7.0–7.5. Lysosomal enzymes (typically expressed with Tags or as Fc-fusions for purification) bind via the tag-Protein A interaction. Wash with PBS to remove HCP and DNA. Elute with low pH buffer (citrate, pH 3.0–3.5). Single step achieves >95% purity.
Yield: 85–95%
Purity: >95%
3
Viral Inactivation
Low pH Viral Inactivation
Hold the Protein A eluate at pH 3.5–3.8 for 30–60 minutes at room temperature. This inactivates enveloped viruses. Neutralize afterward to pH 5.0–6.0 with Tris or phosphate buffer. Monitor pH and time carefully per ICH Q5A guidelines.
4
Polishing
Anion Exchange Chromatography
Load viral-inactivated pool onto anion exchange resin (Q Sepharose or Capto Q) at pH 7.5–8.0. Many lysosomal enzymes have pI values in the 4–6 range, making them negative at this pH and enabling bind-and-elute mode. HCP, DNA, and endotoxin are removed as impurities or in flow-through. Elute with NaCl gradient.
Yield: 85–95%
Purity: >98%
5
Ultrafiltration
Concentration & Buffer Exchange
Diafilter into final formulation buffer using 10–30 kDa MWCO membranes (depending on enzyme size). Typical enzymes: 50–100 kDa. Concentrate to final drug substance concentration (typically 5–50 mg/mL). Buffer: histidine, phosphate, or tris with sucrose for stability.
Yield: >95%
Conc: 10–50 mg/mL
6
Filtration
Sterile Filtration & Fill
Pass final bulk through 0.22 μm sterile filter into sterile containers. Perform fill into vials or syringes under Grade A (ISO 5) aseptic conditions. Lyophilize (freeze-dry) if stability requires. Inspect, label, and release per pharmacopeial specifications.
Yield: >99%
Sterility: 0.22 μm filter
Lysosomal Enzyme Products
| Product | Enzyme | Indication | MW (kDa) | Expression System |
|---|
| Cerezyme | Imiglucerase | Gaucher disease type 1 | ~60 | CHO |
| Myozyme | Alglucosidase alfa | Pompe disease | ~110 | CHO |
| Replagal | Agalsidase alfa | Fabry disease | ~100 | Human fibroblasts |
| Fabrazyme | Agalsidase beta | Fabry disease | ~100 | CHO |
| Vpriv | Velaglucerase alfa | Gaucher disease | ~60 | Human fibroblast |
Cost Considerations
| Step | Key Cost Driver | Relative Cost |
|---|
| Clarification | Centrifuge, depth filters | Low–Medium |
| Protein A Capture | Protein A resin | Highest |
| Viral Inactivation | Hold tanks | Low |
| Anion Exchange | Resin, buffers | Medium |
| UF/DF | Membranes, formulation | Medium |
| Sterile Filtration | Filters, fill line | Low |
Protein A chromatography is the dominant cost driver for lysosomal enzyme manufacturing, similar to mAb production. However, the smaller market (rare diseases) makes process intensification and continuous manufacturing particularly attractive. Use
untangle.bio to model costs at your specific scale.
Frequently Asked Questions
How are lysosomal enzymes targeted to affected tissues?
Most lysosomal enzymes are phosphorylated with mannose-6-phosphate (M6P) residues during production in mammalian cells. M6P receptors on cell surfaces recognize and internalize the enzyme into lysosomes. This targeting mechanism is critical for ERT efficacy. Quality control assays verify M6P content per batch.
What is the difference between alglucosidase alfa and avalglucosidase alfa?
Avalglucosidase alfa (Nexviazyme) is a recombinant human GAA with 2 N-linked glycans modified to contain bis-M6P-GlcNAc, significantly increasing mannose targeting compared to alglucosidase alfa (Myozyme). This improves tissue uptake and allows for lower dosing. The downstream processes are similar but expression constructs differ.
Can ERT manufacturing use continuous processing?
Yes, perfusion bioreactors combined with continuous downstream processing are being adopted for ERT manufacturing. Perfusion yields higher volumetric productivity, while continuous chromatography (periodic countercurrent chromatography) reduces resin inventory. This is particularly valuable for rare disease therapies with limited patient populations.
Build Your Lysosomal Enzyme Process
Drag-and-drop the full ERT manufacturing train, simulate mass balance, and estimate production costs.
Open untangle.bio